Eris Lifesciences acquires trademark ‘Zomelis’ from Novartis AG

04 Dec 2019 Evaluate

Eris Lifesciences has acquired trademark ‘Zomelis’ and its associated trademarks from Novartis AG, based at Basel Switzerland for Indian pharmaceuticals market with effect from December 10, 2019. The trademark has been used for marketing Vildagliptin formulations; an oral anti-diabetic drug that has been promoted in India for close to 10 years. The consideration involved in this trademark acquisition is $13 million.

The trademark along with its applicable associate marks presently enjoy sales on a moving annual total (MAT) basis of Rs 63.96 crore.

Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.

Eris Lifesciences Share Price

1407.05 17.35 (1.25%)
19-Dec-2024 11:08 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1802.00
Dr. Reddys Lab 1316.35
Cipla 1484.65
Lupin 2112.30
Zydus Lifesciences 980.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.